Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/85753
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kairys, Paul | - |
dc.contributor.author | Frese, Thomas | - |
dc.contributor.author | Voigt, Paul | - |
dc.contributor.author | Horn, Johannes | - |
dc.contributor.author | Girndt, Matthias | - |
dc.contributor.author | Mikolajczyk, Rafael | - |
dc.date.accessioned | 2022-05-12T07:00:23Z | - |
dc.date.available | 2022-05-12T07:00:23Z | - |
dc.date.issued | 2022 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/87705 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/85753 | - |
dc.description.abstract | Background: Chronic kidney disease is often asymptomatic in its early stages but constitutes a severe burden for patients and causes major healthcare systems costs worldwide. While models for assessing the cost-effectiveness of screening were proposed in the past, they often presented only a limited view. This study aimed to develop a simulation-based German Albuminuria Screening Model (S-GASM) and present some initial applications. Methods: The model consists of an individual-based simulation of disease progression, considering age, gender, body mass index, systolic blood pressure, diabetes, albuminuria, glomerular filtration rate, and quality of life, furthermore, costs of testing, therapy, and renal replacement therapy with parameters based on published evidence. Selected screening scenarios were compared in a cost-effectiveness analysis. Results: Compared to no testing, a simulation of 10 million individuals with a current age distribution of the adult German population and a follow-up until death or the age of 90 shows that a testing of all individuals with diabetes every two years leads to a reduction of the lifetime prevalence of renal replacement therapy from 2.5% to 2.3%. The undiscounted costs of this intervention would be 1164.10 € / QALY (quality-adjusted life year). Considering saved costs for renal replacement therapy, the overall undiscounted costs would be—12581.95 € / QALY. Testing all individuals with diabetes or hypertension and screening the general population reduced the lifetime prevalence even further (to 2.2% and 1.8%, respectively). Both scenarios were cost-saving (undiscounted, - 7127.10 €/QALY and—5439.23 €/QALY). Conclusions: The S-GASM can be used for the comparison of various albuminuria testing strategies. The exemplary analysis demonstrates cost savings through albuminuria testing for individuals with diabetes, diabetes or hypertension, and for population-wide screening. | eng |
dc.description.sponsorship | Publikationsfonds MLU | - |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject.ddc | 614 | - |
dc.title | Development of the simulation-based German albuminuria screening model (S-GASM) for estimating the cost-effectiveness of albuminuria screening in Germany | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | PLOS ONE | - |
local.bibliographicCitation.publishername | PLOS | - |
local.bibliographicCitation.publisherplace | San Francisco, California, US | - |
local.bibliographicCitation.doi | 10.1371/journal.pone.0262227 | - |
local.openaccess | true | - |
local.accessrights.dnb | free | - |
Appears in Collections: | Open Access Publikationen der MLU |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
journal.pone.0262227.pdf | 628.61 kB | Adobe PDF | ![]() View/Open |